Background--The relationship between late stent malapposition (LSM) and adverse cardiovascular events is controversial. Studies are needed to evaluate long-term (>5 years) clinical outcomes of LSM detected by optical coherence tomography (OCT) after drugeluting stent implantation.
Methods
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Population
Using the OCT registry database of Severance Cardiovascular Hospital, we identified patients who underwent DES implantation for de novo coronary lesions from January 2009 to December 2011, as well as poststent and follow-up OCT. 4 OCT examination was performed at the discretion of operators. Exclusion criteria were as follows: (1) DES implanted to treat left main coronary disease, (2) overlapping DESs in the lesion, (3) clinical follow-up after DES implantation <1 year, (4) follow-up OCT performed >1 year after DES implantation, and (5) poor-quality OCT image. 4 Ultimately, 351 patients with 356 lesions were included in this study. 4 Figure 1 shows the flow diagram for patient selection. The DESs were chosen by operators at the time of implantation and included sirolimus-eluting stents (Cypher; Cordis), zotarolimus-eluting stents (Resolute or Integrity; Medtronic), everolimus-eluting stents (Xience V; Abbott Vascular), and biolimus A9-eluting stents (Nobori [Terumo Corp] or Biomatrix [Biosensors International]). The DESs were implanted using conventional techniques. 5 Unfractionated heparin was administered as an initial bolus of 100 IU/ kg, with additional boluses administered during the procedure to achieve an activated clotting time of 250 to 
Clinical Perspective
What Is New?
• The relationship between late stent malapposition noted on routine optical coherence tomography imaging after drugeluting stent implantation and adverse cardiovascular events is still controversial.
• During long-term follow-up (>5 years), the rates of adverse clinical events were similar between patients with and without late stent malapposition.
What Are the Clinical Implications?
• The presence of late stent malapposition on follow-up optical coherence tomography was not associated with adverse cardiac events and does not need to be corrected. 300 seconds. Dual antiplatelet therapy (aspirin and clopidogrel) was provided to each patient until the follow-up OCT was performed. 4 Maintenance or discontinuation of dual antiplatelet therapy after the follow-up OCT was at the discretion of treating physicians. The study protocol was approved by the institutional review board of our hospital, and written informed consent was obtained from each patient.
OCT Imaging and Analyses
We used 2 OCT systems in this study (M2 and C7-XR imaging systems; LightLab Imaging, St. Jude Medical). 6 All OCT images were analyzed at a core laboratory (Cardiovascular Research Center, Seoul, Korea) by analysts who were blinded to patient and procedural information. 4 Cross-sectional OCT images were analyzed at 1-mm intervals. A malapposed strut was defined as a strut that was detached from the vessel wall as follows: Cypher, ≥160 lm; Resolute or Integrity, ≥110 lm; Xience V, ≥100 lm; Nobori or Biomatrix, ≥130 lm. 7 A coronary stent malapposition detected immediately after DES implantation is classified as acute stent malapposition, whereas one that is detected later (during follow-up OCT) is classified as LSM.
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LSM can be further classified as late-persistent or late-acquired stent malapposition. A late-persistent stent malapposition is an acute stent malapposition that remains present at the followup OCT. A late-acquired stent malapposition is a newly developed stent malapposition that is identified on follow-up OCT despite complete stent apposition on immediate poststent OCT. 4 If malapposed struts were detected by poststent OCT (ie, acute stent malapposition), each cross-section of the poststent OCT image was matched with cross-sections of the follow-up OCT image as accurately as possible based on the distance from fiduciary landmarks (eg, stent edges, side branches, or calcification). 4, 8 The lesions were then classified as resolved acute stent malapposition lesions with or without late-acquired stent malapposition or as late-persistent stent malapposition lesions with or without late-acquired stent malapposition 4 ( Figure 2 ). We then divided the patients into the following 2 groups: patients with LSM (subgroups 1, 2, 4, and 5 in Figure 2 ) and patients without LSM (subgroups 3 and 6 in Figure 2 ).
Clinical Follow-up
All patients were advised to maintain dual antiplatelet therapy (aspirin and clopidogrel) for ≥6 months after DES implantation. 4 During the follow-up period, most patients had a regular follow-up visit at an outpatient clinic. We investigated clinical events that were possibly related to LSM by reviewing medical records at our institute until the date of the last office visit. These events included cardiovascular death, target-lesionand target vessel-related nonfatal myocardial infarction, target-lesion and target-vessel revascularization, and stent thrombosis. These clinical events were defined according to the recommendations of the Academic Research Consortium. 9 The event rates of each group were compared.
Statistical Analyses
Categorical variables are presented as number (percentage) and were compared using v 2 or Fisher exact tests. Continuous variables are presented as meanAESD and were compared using Student t tests. Cumulative rates of composite clinical events (cardiovascular death, target-vesselrelated myocardial infarction, target-vessel revascularization, and stent thrombosis) were estimated with the Kaplan-Meier method and compared among the groups with the log-rank test. We estimated hazard ratios with 95% CIs for the association of LSM with the composite events (cardiovascular death, target-vessel-related myocardial infarction, target vessel revascularization, and stent thrombosis) by Cox regression analysis, adjusted for baseline clinical and procedural variables. Variables with P<0.05 from univariate analyses were included in the analysis. Statistical analyses were performed using SPSS (v25.0; IBM Corp). P<0.05 was considered significant.
Results
The mean follow-up duration after DES implantation was 80.1AE24.5 months, and follow-up OCT was performed on average 175AE60 days after DES implantation. 4 Even though LSM was identified at follow-up OCT, no interventional procedure was performed for the lesions with LSM. Patients were divided into the following groups based on acute, latepersistent, or late-acquired stent malapposition detected by poststent and follow-up OCT: patients with LSM (subgroups 1, 2, 4, and 5 in Figure 3 ; 99 patients with 99 lesions) versus patients without LSM (subgroups 3 and 6 in Figure 3 ; 252 patients with 257 lesions). Baseline characteristics of the 2 groups are summarized in Table 1 . Compared with patients without LSM, those with LSM showed a higher rate of calcified lesions, larger reference vessel diameter, higher preintervention percentage diameter stenosis, and larger stent diameter. We compared clinical events for these 2 groups and found that the rates of individual and composite events were similar (Table 2) . No very late stent thrombosis occurred in either group. Figure 4 shows the Kaplan-Meier curves for the composite events of cardiovascular death, target-vesselrelated myocardial infarction, target-vessel revascularization, and stent thrombosis. The cumulative 8-year rate of composite events was 7.3% in patients with LSM and 10.5% in patients without LSM (P=0.822 by log-rank test). We further divided patients into the following 4 groups: late-persistent stent malapposition alone (subgroup 1; 45 patients with 45 lesions), both late-persistent and late-acquired stent malapposition (subgroup 2; 23 patients with 23 lesions), late-acquired stent malapposition alone (subgroups 4 and 5; 31 patients with 31 lesions), and no LSM (subgroups 3 and 6; 252 patients with 257 lesions). The cumulative 8-year rates of composite events were also similar among these 4 groups (9.6%, 0%, 9.7%, and 10.5%, respectively; P=0.468 by log-rank test; Figure 5 ).
Of all 351 enrolled patients, 269 patients (77%) were treated with new-generation DESs and the other 82 patients (23%) were treated with a first-generation DES. The number of patients with late-persistent stent malapposition was 31 (12%) with new-generation DESs and 14 (17%) with first-generation DES (P=0.188). The number of patients with late-acquired stent malapposition was 41 (15%) with new-generation DESs and 13 (16%) with a first-generation DES (P=0.893). In all 99 patients with LSM, the cumulative 8-year rates of composite events were compared for patients with lateacquired stent malapposition (subgroups 2, 4, and 5) versus those with late-persistent stent malapposition (subgroup 1; Figure 6A ), with malapposition distance ≥400 versus <400 lm ( Figure 6B) , and with malapposition length ≥1 versus <1 mm ( Figure 6C ). None of these comparisons achieved statistically significant differences.
LSM on follow-up OCT and variables with P<0.05 from univariate analyses were entered into the Cox regression model to identify independent predictors of the composite events and to calculate their adjusted hazard ratio (Table 3) . LSM on followup OCT was not the independent predictor of the composite events (hazard ratio: 0.48; 95% CI, 0.13-1.79; P=0.273).
Discussion
During long-term follow-up after DES implantation (80.1AE24.5 months), the cumulative rates of composite events did not differ significantly for patients with versus without OCT-detected LSM. To the best of our knowledge, this study is unique in its long-term follow-up (>5 years) for evaluation of clinical outcomes of OCT-detected LSM and its larger number of patients. Most studies evaluating long-term clinical outcomes in patients with LSM after DES were performed with IVUS. The use of both poststent and follow-up IVUS evaluations can discriminate late-acquired stent malapposition from late-persistent stent malapposition. Hong et al reported favorable long-term (3 years) clinical outcomes in 80 patients with late-acquired stent malapposition among 532 DES-treated patients who underwent both poststent and follow-up IVUS examinations. 10, 11 Other studies have also reported favorable longterm clinical outcomes in patients treated with a bare-metal stent or DES who had late-acquired stent malapposition.
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However, a study of 195 DES-treated patients suggested that late-acquired stent malapposition may have been a risk factor for late DES thrombosis in 23 patients with late-acquired stent malapposition. 15 Furthermore, 5-year follow-up of 194 DEStreated patients reported that LSM (late-acquired or latepersistent) was associated with a higher rate of very late DES thrombosis in 37 patients with LSM. 16 Unfortunately, discrimination between late-acquired and late-persistent stent malapposition was not possible in that study because poststent IVUS data were not available. 16 Of note, patients in those previous studies were treated with first-generation DESs. [10] [11] [12] [13] [14] [15] [16] Because of these conflicting results, the relationship between IVUSdetected LSM and adverse cardiovascular events remains unclear.
1,17
Stent malapposition can be more reliably detected by OCT than by IVUS 1 ; however, few studies evaluating long-term clinical outcomes of patients with OCT-detected LSM have had adequate sample sizes. The proportion of malapposed stent struts detected by OCT (up to 50% of stents implanted) is higher than the proportion detected by IVUS (%15% of stents implanted). 1, 18 We previously reported that LSM was frequently detected in 351 DES-treated patients who underwent both poststent and follow-up OCT examination, but clinical outcomes of the patients with LSM (late-acquired or late-persistent) were favorable during the 2-year follow-up period. 4 The population of that study was the DES-treated patients who underwent routine OCT imaging and had a follow-up observation of subsequent adverse events in daily clinical practice. In the present study, we evaluated these patients over a longer follow-up period and found no significant difference in rates of adverse events of patients with versus without LSM. In contrast, 3 recent registry studies of patients presenting with stent thrombosis consistently identified stent malapposition as a frequent underlying abnormality. 1, [19] [20] [21] Therefore, the European expert consensus recently recommended that extensively malapposed struts should be avoided following stent implantation and should be corrected when anatomically feasible. 1 However, the participants in those studies were highly selected patients who suffered from rare stent thrombosis, not the general DEStreated patients. In addition, stent malapposition was not the only finding responsible for stent thrombosis. Other stent abnormalities such as underexpansion or uncovered struts were also identified in some patients with stent thrombosis and stent malapposition. [19] [20] [21] Considering the high frequency of OCT-detected stent malapposition in daily clinical practice, 1, 4, 18 the number of patients with OCT-detected stent malapposition Figure 6 . Cumulative 8-year rate of composite events (cardiovascular death, target-vessel-related myocardial infarction, target-vessel revascularization, and stent thrombosis), as estimated by Kaplan-Meier curves for patients with late-acquired vs late-persistent stent malapposition (A), malapposition distance ≥400 vs <400 lm (B), and malapposition length ≥1 vs <1 mm (C). 22, 23 In the present study, no very late stent thrombosis occurred in patients with OCT-detected LSM during 80.5AE19.8 months of follow-up. According to our results, the simple presence of LSM on follow-up OCT was not associated with adverse cardiac events and did not need to be corrected. Even after the discontinuation of dual antiplatelet therapy, hard end points such as cardiovascular death, myocardial infarction, or stent thrombosis had not occurred in patients with LSM.
The favorable clinical outcomes observed in the present study may be explained as follows. 4 First, although large-sized stent malapposition has been associated with late stent thrombosis, small-sized stent malapposition that was detected by OCT may not have a clinically important effect. 4, 24 Second, continuous neointimal healing during the follow-up period may decrease stent malapposition. 4, 25, 26 Third, most lesions (77%)
were implanted with a new-generation DES in this study. 4 The current study has several limitations. First, our study has potential selection bias because of its cross-sectional design and relatively small number of patients. Of all patients implanted with a DES, a small proportion were included and analyzed in this study. They were stable patients who underwent follow-up OCT without additional intervention. This might have caused sampling bias. Second, patients treated with firstgeneration DESs were also included in the study, and this limits the general application of our results to the current clinical field. Third, the rate of hard end points such as cardiovascular death, myocardial infarction, and stent thrombosis was low, suggesting the possibility of a low-risk population.
Conclusions
During 80.1AE24.5 months of follow-up, very late stent thrombosis did not occur in 351 patients with OCT-detected LSM. The rates of adverse clinical events were similar for patients with and those without LSM.
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